دورية أكاديمية
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy
| العنوان: | Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy |
|---|---|
| المؤلفون: | Rossouw, Jacques E., Johnson, Karen C., Pettinger, Mary, Cushman, Mary, Sandset, Per Morten, Kuller, Lewis, Rosendaal, Frits, Rosing, Jan, Wasserthal-Smoller, Sylvia, Martin, Lisa W., Manson, JoAnn E., Lakshminarayan, Kamakshi, Merino, Jose G., Lynch, John |
| المصدر: | Rossouw , J E , Johnson , K C , Pettinger , M , Cushman , M , Sandset , P M , Kuller , L , Rosendaal , F , Rosing , J , Wasserthal-Smoller , S , Martin , L W , Manson , J E , Lakshminarayan , K , Merino , J G & Lynch , J 2012 , ' Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy ' , Stroke , vol. 43 , no. 4 , pp. 952-957 . https://doi.org/10.1161/STROKEAHA.111.643072Test |
| سنة النشر: | 2012 |
| المجموعة: | Maastricht University Research Publications |
| مصطلحات موضوعية: | cerebrovascular accident, estrogen, hemostasis, menopause, randomized controlled trials |
| الوصف: | Background and Purpose-To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy. Methods-Nested case-control study of 455 cases of ischemic stroke and 565 matched control subjects in the Women's Health Initiative trials of postmenopausal hormone therapy. Results-Baseline free TFPI was associated with ischemic stroke risk (OR per SD increase, 1.17; 95% CI, 1.01-1.37; P=0.039), but baseline nAPCsr was not (OR per SD increase, 0.89; 95% CI, 0.75-1.05; P=0.15). Baseline TFPI levels and nAPCsr did not modify the effect of postmenopausal hormone therapy on ischemic stroke. Treatment-induced mean changes of -28% in free TFPI and +65% in nAPCsr did not change the risk of ischemic stroke (interaction P=0.452 and 0.971, respectively). In subgroup analyses, baseline nAPCsr was inversely associated with lacunar strokes (OR per SD increase, 0.74; 95% CI, 0.57-0.96; P=0.025) and baseline free TFPI interacted with treatment to increase large vessel atherosclerotic strokes (P=0.008). Conclusions-Procoagulant changes in TFPI or nAPCsr do not modify the increased ischemic stroke risk due to postmenopausal hormone therapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1161/STROKEAHA.111.643072 |
| الإتاحة: | https://doi.org/10.1161/STROKEAHA.111.643072Test https://cris.maastrichtuniversity.nl/en/publications/02420462-0c4f-438f-901b-bbfd1429fe83Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.43C33F86 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/STROKEAHA.111.643072 |
|---|